This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lowell, G. H. Articles by Colleton, C. Search for Related Content PubMed PubMed Citation Articles by Lowell, G. H. Articles by Colleton, C.

 Previous Article  |  Next Article 

Infect. Immun., 05 1996, 1706-1713, Vol 64, No. 5
Copyright © 1996, American Society for Microbiology

Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice

GH Lowell, RW Kaminski, S Grate, RE Hunt, C Charney, S Zimmer and C Colleton
Division of Pathology, Walter Reed Army Institute of Research, Washington, DC 20307, USA.

Intranasal or intramuscular (i.m.) immunization of mice and i.m. immunization of rabbits with formalinized staphylococcal enterotoxin B (SEB) toxoid in saline elicited higher anti-SEB serum immunoglobulin G (IgG) titers when the toxoid was formulated with proteosomes. In addition, intranasal immunization of mice with this proteosome-toxoid vaccine elicited high levels of anti-SEB IgA in lung and intestinal secretions, whereas the toxoid without proteosomes did not. Two i.m. immunizations with proteosome-toxoid plus alum also induced higher murine serum responses than alum-adjuvanted toxoid without proteosomes. Furthermore, proteosome-toxoid delivered intranasally in saline or i.m. with either saline or alum afforded significant protection against lethal SEB challenge in two D-galactosamine-sensitized murine models of SEB intoxication, i.e., the previously described i.m. challenge model and a new respiratory challenge model of mucosal SEB exposure. Efficacy correlated with the induction of high serum levels of anti-SEB IgG. In contrast, intranasal or i.m. immunization with toxoid in saline without proteosomes was not significantly protective in either challenge model. Proteosome-toxoid plus alum given i.m. also elicited more significant protection against respiratory challenge than the alum-adjuvanted toxoid alone. The capacity of proteosomes to enhance both i.m. and intranasal immunogenicity and efficacy of SEB toxoid indicates that testing such proteosome-SEB toxoid vaccines in the nonhuman primate aerosol challenge model of SEB intoxication prior to immunogenicity trials in humans is warranted. These data expand the applicability of the proteosome mucosal vaccine delivery system to protein toxoids and suggest that respiratory delivery of proteosome vaccines may be practical for enhancement of both mucosal and systemic immunity against toxic or infectious diseases.

This article has been cited by other articles:

• Hu, D.-L., Cui, J.-C., Omoe, K., Sashinami, H., Yokomizo, Y., Shinagawa, K., Nakane, A. (2005). A Mutant of Staphylococcal Enterotoxin C Devoid of Bacterial Superantigenic Activity Elicits a Th2 Immune Response for Protection against Staphylococcus aureus Infection. Infect. Immun. 73: 174-180 [Abstract] [Full Text]  
• Fries, L. F., Montemarano, A. D., Mallett, C. P., Taylor, D. N., Hale, T. L., Lowell, G. H. (2001). Safety and Immunogenicity of a Proteosome-Shigella flexneri 2a Lipopolysaccharide Vaccine Administered Intranasally to Healthy Adults. Infect. Immun. 69: 4545-4553 [Abstract] [Full Text]  
• Arad, G., Hillman, D., Levy, R., Kaempfer, R. (2001). Superantigen antagonist blocks Th1 cytokine gene induction and lethal shock. J. Leukoc. Biol. 69: 921-927 [Abstract] [Full Text]  
• Stiles, B. G., Garza, A. R., Ulrich, R. G., Boles, J. W. (2001). Mucosal Vaccination with Recombinantly Attenuated Staphylococcal Enterotoxin B and Protection in a Murine Model. Infect. Immun. 69: 2031-2036 [Abstract] [Full Text]  
• Childers, N. K., Miller, K. L., Tong, G., Llarena, J. C., Greenway, T., Ulrich, J. T., Michalek, S. M. (2000). Adjuvant Activity of Monophosphoryl Lipid A for Nasal and Oral Immunization with Soluble or Liposome-Associated Antigen. Infect. Immun. 68: 5509-5516 [Abstract] [Full Text]  
• Hume, E. B. H., Dajcs, J. J., Moreau, J. M., O'Callaghan, R. J. (2000). Immunization with Alpha-Toxin Toxoid Protects the Cornea against Tissue Damage during Experimental Staphylococcus aureus Keratitis. Infect. Immun. 68: 6052-6055 [Abstract] [Full Text]  
• Oftung, F., Nass, L. M., Wetzler, L. M., Korsvold, G. E., Aase, A., Hoiby, E. A., Dalseg, R., Holst, J., Michaelsen, T. E., Haneberg, B. (1999). Antigen-Specific T-Cell Responses in Humans after Intranasal Immunization with a Meningococcal Serogroup B Outer Membrane Vesicle Vaccine. Infect. Immun. 67: 921-927 [Abstract] [Full Text]  
• Saunders, N. B., Shoemaker, D. R., Brandt, B. L., Moran, E. E., Larsen, T., Zollinger, W. D. (1999). Immunogenicity of Intranasally Administered Meningococcal Native Outer Membrane Vesicles in Mice. Infect. Immun. 67: 113-119 [Abstract] [Full Text]  
• Wortham, C., Grinberg, L., Kaslow, D. C., Briles, D. E., McDaniel, L. S., Lees, A., Flora, M., Snapper, C. M., Mond, J. J. (1998). Enhanced Protective Antibody Responses to PspA after Intranasal or Subcutaneous Injections of PspA Genetically Fused to Granulocyte-Macrophage Colony-Stimulating Factor or Interleukin-2. Infect. Immun. 66: 1513-1520 [Abstract] [Full Text]  
• VanCott, T. C., Kaminski, R. W., Mascola, J. R., Kalyanaraman, V. S., Wassef, N. M., Alving, C. R., Ulrich, J.T., Lowell, G. H., Birx, D. L. (1998). HIV-1 Neutralizing Antibodies in the Genital and Respiratory Tracts of Mice Intranasally Immunized with Oligomeric gp160. J. Immunol. 160: 2000-2012 [Abstract] [Full Text]